共 15 条
[1]
The HRAS1 minisatellite locus and risk of ovarian cancer. Weitzel JN,Ding S,Larson GP. Cancer Research . 2000
[2]
Assessment of ovarian tumor vascularity with transvaginal clolr Doppler sonography. Gleischer AC,Rodgers WH,Rao BK,et al. Journal of Ultrasound in Medicine . 1991
[3]
Blood flow characteristics of ovarian tumors: Implications for ovarian cancer screening. Carter JR,Lau M,Fowler JM,et al. American Journal of Obstetrics and Gynecology . 1995
[4]
An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Suzuki S,Moore DH,Gray JW. Cancer Research . 2000
[5]
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. Menon U,Talaat A,Rosenthal AN. Brtish Journal of Obstetrics and Gynaecology . 2000
[6]
Estrogen regulation fo TGF-alpha in ovarian cancer. Simpson BJ,Langdon SP,Rabiasz GL,et al. Journal of Steroid Biochemistry . 1998
[7]
Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Lerner JP,Timor-Tristch IE,Federmam A,et al. American Journal of Obstetrics and Gynecology . 1994
[8]
Cdr2, a target antigen of naturally occurring human trmor immunity, is widely expressed in gynecological tumors. Darnell JC,Albert ML,Darnell RB. Cancer Research . 2000
[9]
Transvaginal sonographic characterization of ovarian diseases: Evaluation of a new scoring system to predict malignancy. Sassone AM,Timor-Tritsch IE,Artner A,et al. Obstetrics and Gynecology . 1991
[10]
Cancer screening in the postmenopausal women. Seltzer V. Clinical Obstetrics and Gynecology . 1996